Danaher (NYSE:DHR) Issues Earnings Results, Beats Expectations By $0.12 EPS

Danaher (NYSE:DHR) issued its earnings results on Tuesday. The conglomerate reported $2.06 EPS for the quarter, beating analysts’ consensus estimates of $1.94 by $0.12, FiscalAI reports. Danaher had a return on equity of 10.96% and a net margin of 14.89%.The business had revenue of $5.95 billion during the quarter, compared to analyst estimates of $6 billion. During the same period in the previous year, the company posted $1.88 EPS. The firm’s revenue was up 3.7% compared to the same quarter last year. Danaher updated its FY 2026 guidance to 8.350-8.550 EPS.

Here are the key takeaways from Danaher’s conference call:

• Q1 results — Sales were $6.0 billion, core revenue rose 0.5% year?over?year, adjusted diluted EPS was $2.06 (+9.5% YoY), adjusted operating margin improved to 30.2% (+60 bps), and free cash flow was $1.1 billion (105% conversion).
• Respiratory headwind — A lighter than normal Q1 respiratory season drove a ~2.5% core revenue headwind and Cepheid respiratory revenue declined about 25% YoY, with Danaher now expecting full?year respiratory revenue of roughly $1.6–$1.7 billion.
• Bioprocessing strength — Biotechnology/bioprocessing core revenue grew 7%, consumables grew high single digits, and equipment orders were >30% YoY, which management says signals the start of a multi?year capacity investment cycle.
• Masimo acquisition — Pending purchase of Masimo is expected to be accretive in the first full year, deliver high?single?digit ROIC by year five, and drive about $125 million of cost synergies plus ~$50 million of revenue synergies by year five.
• Guidance and balance sheet — Danaher raised full?year adjusted diluted EPS to $8.35–$8.55 (narrowed/upside), kept core revenue growth guidance at 3–6%, expects Q2 core revenue up low single digits and a ~26.5% adjusted operating margin, and highlights >$5 billion expected 2026 free cash flow to support further capital deployment.

Danaher Trading Down 5.4%

Danaher stock opened at $184.11 on Thursday. The stock has a market cap of $130.30 billion, a P/E ratio of 35.61, a PEG ratio of 2.64 and a beta of 0.95. Danaher has a fifty-two week low of $180.03 and a fifty-two week high of $242.80. The firm’s fifty day moving average price is $197.17 and its 200-day moving average price is $214.35. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.51 and a current ratio of 1.87.

Danaher Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, April 24th. Shareholders of record on Friday, March 27th will be given a dividend of $0.40 per share. This is an increase from Danaher’s previous quarterly dividend of $0.32. This represents a $1.60 annualized dividend and a dividend yield of 0.9%. The ex-dividend date is Friday, March 27th. Danaher’s dividend payout ratio (DPR) is currently 30.95%.

Insider Buying and Selling at Danaher

In other news, EVP Gregory M. Milosevich sold 1,320 shares of the company’s stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $208.01, for a total value of $274,573.20. Following the transaction, the executive vice president owned 5,099 shares of the company’s stock, valued at approximately $1,060,642.99. This represents a 20.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 10.80% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. GW&K Investment Management LLC increased its holdings in shares of Danaher by 8.4% in the fourth quarter. GW&K Investment Management LLC now owns 605 shares of the conglomerate’s stock worth $138,000 after purchasing an additional 47 shares during the period. Kestra Private Wealth Services LLC increased its holdings in shares of Danaher by 0.3% in the third quarter. Kestra Private Wealth Services LLC now owns 15,421 shares of the conglomerate’s stock worth $3,057,000 after purchasing an additional 48 shares during the period. Snowden Capital Advisors LLC increased its holdings in shares of Danaher by 0.6% in the second quarter. Snowden Capital Advisors LLC now owns 9,919 shares of the conglomerate’s stock worth $1,963,000 after purchasing an additional 55 shares during the period. Cloud Capital Management LLC increased its holdings in shares of Danaher by 2.8% in the fourth quarter. Cloud Capital Management LLC now owns 2,112 shares of the conglomerate’s stock worth $484,000 after purchasing an additional 57 shares during the period. Finally, CYBER HORNET ETFs LLC increased its holdings in shares of Danaher by 3.6% in the third quarter. CYBER HORNET ETFs LLC now owns 1,750 shares of the conglomerate’s stock worth $347,000 after purchasing an additional 61 shares during the period. Institutional investors own 79.05% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have commented on DHR shares. Rothschild & Co Redburn set a $205.00 price objective on Danaher in a report on Friday, April 17th. Wolfe Research dropped their price objective on Danaher from $260.00 to $230.00 and set an “outperform” rating on the stock in a research note on Wednesday, April 8th. Barclays dropped their target price on Danaher from $250.00 to $230.00 and set an “overweight” rating on the stock in a research report on Tuesday, April 14th. UBS Group dropped their target price on Danaher from $270.00 to $250.00 and set a “buy” rating on the stock in a research report on Wednesday. Finally, Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Danaher in a research report on Thursday, January 29th. Seventeen research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, Danaher presently has a consensus rating of “Moderate Buy” and an average price target of $243.20.

Key Danaher News

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: EPS beat and slight guidance lift — Danaher beat Q1 non?GAAP EPS estimates and raised the upper end of FY2026 EPS guidance, driven by Bioprocessing and Life Sciences strength. Read More.
• Positive Sentiment: Analyst upgrade/raise from Evercore — Evercore raised its DHR target (to $232) and kept an outperform view, signaling some buy?side conviction on longer?term momentum. Read More.
• Neutral Sentiment: € senior?notes offering — Danaher priced €3.0B (net) of euro?denominated senior notes across 2028–2038 maturities to raise ~€2.98B net proceeds; this funds corporate needs (and potentially M&A) but increases outstanding debt capacity. Read More.
• Neutral Sentiment: Mixed longer?term analyst view — while several firms still carry Buy/Outperform ratings and a median multi?quarter target above current levels, recent updates show varied target changes across shops. Read More.
• Negative Sentiment: Multiple price?target cuts — Several major houses trimmed targets (examples: JPMorgan to $245, Guggenheim to $235, TD Cowen/Wells Fargo adjustments), putting near?term pressure on the stock. Read More. Read More. Read More.
• Negative Sentiment: Revenue miss and Diagnostics softness — headline revenue lagged expectations and management flagged weaker Diagnostics (Cepheid/respiratory seasonality), leaving questions about near?term demand. Read More.
• Negative Sentiment: Insider selling and investor positioning — recent disclosures and institutional shifts (noted in market trackers) may amplify selling pressure while the market digests the cadence of core growth versus FX and M&A execution risks. Read More.

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.